117 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.2
ADAP
Adaptimmune Therapeutics Plc
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
gd62r06
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
94g9277r5f e60xm5f
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
8t3g rnemjwk2jxt8
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
8-K
EX-10.1
p0b5a f93o9t91
6 Mar 23
Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update
6:47am
425
EX-10.2
svr4k09
6 Mar 23
Business combination disclosure
6:36am
425
EX-10.1
ejgr8cc0fkebfyebzeq
6 Mar 23
Business combination disclosure
6:36am
8-K
EX-10.2
bbmbfx 0qieexuu
6 Mar 23
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
6:34am
8-K
EX-10.1
rwgn3isafp4rsm
6 Mar 23
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
6:34am
8-K
EX-10.1
wg0iog 5818fr
16 Feb 23
Adaptimmune Announces Changes to Board of Directors
8:14am
8-K
EX-10.1
vrrakr 3ueetz
20 Dec 22
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-10.1
96de9a uyf0w30
15 Jun 22
Entry into a Material Definitive Agreement
4:10pm
8-K
EX-10.2
o60oaabmckak
15 Jun 22
Entry into a Material Definitive Agreement
4:10pm
8-K
EX-10.1
rxuysk2cg fe
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.01
mqke1sf8905613blu9z
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am